Call For Entries: International Bureau for Epilepsy and UCB launch the 2012 Excellence in Epilepsy Journalism Award to recognise exceptional reporting on epilepsy
Post-hoc analysis indicated that timing and magnitude of initial response to certolizumab pegol predicted likelihood of low disease activity at week 28 in patients with active moderate to severe rheumatoid arthritis
Two dosing regimens of certolizumab pegol demonstrated comparable efficacy in maintaining clinical response versus placebo in patients with moderate to severe rheumatoid arthritis
